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ABSTRACT 
Objective: Cefuroxime axetil, a prodrug of Cefuroxime, is a poorly water soluble drug, thus it has got only limited solubility and dissolution rate in 
gastric fluids. Also, the bioavailability of Cefuroxime axetil oral suspension is only 40-45% when compared to the 60% bioavailability of tablets. The 
objective of this study was to develop an oral suspension of Cefuroxime axetil with improved oral bioavailability by inclusion complexation method 
using Hydroxypropyl beta cyclodextrin [HP-Beta-cylcodextrin]  
Methods: The complexation of Cefuroxime axetil and HP-Beta cyclodextrin was carried out at 1:1, 1:2, 1:2.5 and 1:3 ratios respectively. The 
prepared suspensions were evaluated for various parameters like pH, viscosity, re-dispersibility, pourability, and assay and in-vitro dissolution 
profile. A leading marketed product and the optimized formulation were evaluated for the pharmacokinetic parameters like Cmax, AUC0-t, AUC0-∞ 
Results: Considering the in-vitro dissolution profile, formulation with 1:2.5 ratios of Cefuroxime axetil and HP-Beta cyclodextrin was selected as the 
optimized formulation. The Cmax of Optimized formulation and Marketed product were 148±1.26ng/ml and 126±1.52 ng/ml respectively, and the 
AUC
and Tmax in healthy adult male rabbits. 
0-t of  
Conclusion: From the results obtained it can be observed that there is a significant improvement in the bioavailability of optimized formulation 
compared to the marketed product. This demonstrates that the inclusion complexation method with HP-Beta cyclodextrin can significantly improve 
the oral bioavailability of Cefuroxime axetil. 
Optimized formulation and Marketed product were 989±16.42 ng. h/ml and 613±24.26 ng. h/ml respectively, which shows a significant 
improvement in the bioavailability of optimized formulation 
Keywords: Cefuroxime axetil, Bioavailability, Beta cyclodextrin, Inclusion complexation 
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INTRODUCTION 
Cefuroxime axetil is a prodrug of Cefuroxime, which is a second-
generation cephalosporin antibiotic with activity against wide range 
of organisms. The bactericidal activity of cefuroxime axetil is due to 
Cefuroxime’s binding to essential target proteins and the resultant 
inhibition of bacterial cell wall synthesis. After oral administration, 
Cefuroxime axetil is absorbed and then rapidly hydrolyzed by the 
nonspecific esterases which is distributed in the intestinal mucosa 
and portal blood, and ultimately transformed into the 
pharmacologically active Cefuroxime [1-3]. 
Cefuroxime axetil is a poorly water soluble drug; thus, it has got only 
limited solubility and dissolution rate in gastric fluids. The 
bioavailability of oral suspension is only 40-45% when compared to 
the 60% bioavailability of tablets. Therefore, the oral suspension 
and tablets cannot be substituted each other on mg/mg basis [4-6]. 
In this study attempt has been made to improve the oral 
bioavailability of Cefuroxime axetil oral suspension 125 mg by 
inclusion complexation method using HP-Beta cyclodextrin. 
Cyclodextrins are having a ‘bucket-like’ structure, which allows 
them to accommodate guest molecules within its cavity, so forming 
an inclusion complexation, which helps in improving the solubility, 
oral bioavailability, and stability of a variety of drugs [7-15]. In this 
study, HP-beta-cyclodextrin is selected due to its improved water 
solubility and safety compared to other cyclodextrins [16]. A leading 
marketed sample is used in this study as a competitor product, 
which has used spray drying technology with Stearic acid to mask 
the taste [17, 18]. A comparative evaluation of prepared oral 
suspensions and marketed product has been conducted for various 
in-vitro and in-vivo parameters. 
MATERIALS AND METHODS 
Materials 
Cefuroxime axetil for the study was procured from Covalent 
Laboratories private limited, Hyderabad, India. HP-Beta cyclodextrin 
was purchased from Signet Chemical Corporation Pvt ltd, India (mfg. 
by: Roquette). Sucrose was received from EID Parry Ltd, India; 
Xanthan was procured from Deosen, China. Acesulfame potassium 
was procured from Ningbo Hi-Tech Biochemicals Co-Ltd China. 
Aspartame was received from NutraSweet, China. Tutti fruity flavor 
and Peppermint flavor were procured from Firmenich, Switzerland.  
Methods  
Preparation of cefuroxime axetil: HP-beta-cyclodextrin complex 
by inclusion complexation method 
Cefuroxime axetil and HP-Beta cyclodextrin were taken at 1:1, 1:2, 1:2.5 
and 1:3 combinations at molecular weight ratio (shown in table-1).
 
Table 1: Combinations of cefuroxime axetil and HP-beta cyclodextrin for complexation 
Ingredients Ratio (mg/5 ml) 
1:1 1:2 1:2.5 1:3 
Cefuroxime axetil 158.250 158.250 158.250 158.250 
HP-Beta-cylcodextrin 477.915 955.830 1194.790 1433.750 
Total weight 636.165 1114.080 1353.040 1592.000 
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Accurately weighed Cefuroxime axetil and HP-Beta cyclodextrin 
were sifted through #30 mesh and mixed together to get a uniform 
blend. The resulting mixture was slowly added to purified water in a 
beaker under stirring using mechanical stirrer. The stirring process 
continued for six hours to get thick slurry of Cefuroxime axetil and 
HP-Beta-cylcodextrin complex.  
The slurry was transferred to a tray and dried in hot air oven at 45 
°C until the complex is adequately dried. The dried complex was 
passed through #60 mesh and mixed thoroughly. The resulted 
Cefuroxine axetil: HP-Beta-cylcodextrin complex in different ratios 
were used for further processing to make dry suspension. 
Preparation of taste masked dry suspension of cefuroxime 
axetil 125 mg/5 ml 
Cefuroxime axetil taste masked dry suspension was formulated by 
mixing Cefuroxime axetil: HP Beta-cylcodextrin complex along with 
other inactive ingredients as shown in table 2. Formulations were 
prepared with each combination of Cefuroxime axetil: HP Beta-
cylcodextrin complexes (1:1, 1:2, 1:2.5 and 1:3). 
 
Table 2: Formula for cefuroxime axetil taste masked dry suspension 125 mg/5 ml 
S. No. Ingredients Ratio (mg/5 ml) 
1:1 1:2 1:2.5 1:3 
1 Cefuroxime axetil: HP Beta-cylcodextrin complex 636.165 1176.468 1454.518 1634.984 
2 Sucrose (#40 mesh grade)  1691.876 1286.649 1078.111 942.762 
3 Sucrose (#80 mesh grade)  563.959 428.883 359.371 314.254 
4 Acesulfame K 25.000 25.000 25.000 25.000 
5 Aspartame 30.000 30.000 30.000 30.000 
6 Xanthan gum  8.000 8.000 8.000 8.000 
7 Tutty friuty premium flavour 35.000 35.000 35.000 35.000 
8 Peppermint premium flavour 10.000 10.000 10.000 10.000 
 Average weight:  3000.000 3000.000 3000.000 3000.000 
Cefuroxime axetil: HP-Beta-cylcodextrin complex, Sucrose (#80 mesh), Acesulfame K, Aspartame, Xanthan gum, Tutti fruity flavor and Peppermint 
premium flavor were sifted through mesh # 40 and mixed together. Sucrose (# 40 mesh) was sifted through mesh #30 and added to above blend 
and mixed well. 18g of the blend was filled in 30 ml High-density polyethylene [HDPE] bottle and closed with HDPE cap. Each bottle needs to be 
reconstituted with water before administration to make the oral suspension. 
 
Evaluation of cefuroxime axetil oral suspension 125 mg/5 ml 
Physiochemical properties of suspension 
The physiochemical properties of suspension like color, pH, 
dispersibility, Viscosity, Assay and pourability were evaluated.  
In-vitro dissolution studies 
In-vitro dissolution of all the combinations and market sample were 
tested using ELECTROLAB dissolution apparatus as per the method 
specified in United States Pharmacopoeia [USP]. 900 ml of pH 7.0 
Phosphate buffer was used as dissolution medium with USP 
apparatus 2 (Paddle), at 50 rotations per minute [rpm]. The 
temperature of the medium was maintained at 37±0.5 °C. The dry 
suspension was reconstituted with water and a quantity equivalent 
to 125 mg of Cefuroxime axetil were used for the dissolution study. 
During the dissolution study, 5 ml samples were withdrawn at 10 
min, 20 min and 30 min intervals. The samples were filtered through 
0.22 µm filter, and the concentration of Cefuroxime axetil in the 
filtrate was tested using a spectrophotometer. The limit for 
dissolution as per USP is not less than 60% (Q) in 30 min. 
Pharmacokinetic study in rabbits 
The bioavailability evaluation of optimized formulation and 
marketed product was carried out at Albino Research and Training 
Institute, Hyderabad, India with approval from the Committee for 
the Purpose of Control And Supervision of Experiments on Animals
Animals and study design 
 
(CPCSEA) for the study with registration no: 1722/ RO/ 
ERe/S/13/CPCSEA. 
Six healthy adult male rabbits (Weighed: 1.5-2 Kg, aged: 8-10 mo) 
were enrolled in the study. Rabbits fasted for 12 h with free access 
to water before the study started. A single dose two-way crossover 
design study was conducted on rabbits. There was a washout period 
of one week between the two doses. The rabbits were divided into 
two groups  
Protocol of study 
Administration of the two products (optimized formulation and 
Marketed product) to the animals was carried by means of a two-
way crossover design. The subjects were randomly divided into two 
equal groups and assigned to one of the two sequences of 
administration. Each animal received a single dose at a time. 
Sampling procedure 
The blood samples were collected from the ear marginal vein of the 
rabbits, which were held in wooden cages, in heparinized glass 
centrifuge tubes with the aid of sterilized disposable plastic syringes 
just before and at 1, 2, 4, 6, 8, 10, 12, 15, 18, 21 and 24h after the 
drug administration. The blood samples were centrifuged at 3000 
rpm for 10 min to separate the plasma for analysis  
Quantitative drug analysis 
The concentration of drug in plasma was determined by HPLC technique 
with ultraviolet detection at 279 nm. Estimation of drug concentration 
was carried out by interpolating the peak area of best formulation on a 
calibration curve of spiked the blank plasma over the range assayed  
Pharmacokinetic analysis  
The pharmacokinetic characteristics such as Cmax (ng/ml), Tmax 
(h), Kel (h-1), t½el (h), Vd (ng/ml), AUC0-24 (ng. h/ml), AUC0-∞ 
(ng. h/ml), AUMC0-24 (ng. h2/ml), AUMC0-∞ (ng. h2/ml), MRT0-24 
(h) and MRT0-∞ (h) of drugs were determined from the plasma 
concentration-time profile. The maximum plasma concentration 
(Cmax) and time to reach maximum plasma concentration (Tmax) 
were obtained directly from the plasma concentration-time data. 
The area under the plasma concentration-time curve up to the last 
time (t) showing a measurable concentration (Ct) of the analyte 
(AUC0-t) was determined by applying the linear trapezoidal rule. 
The apparent elimination rate constant (Kel) was calculated by the 
log-linear regression of the data points of describing a terminal log-
linear decaying phase. The AUC0-∞ values (express the magnitude 
of absorption) were determined by adding the quotient of *Ct and 
the appropriate kel to the corresponding AUC0-t, which is,  
AUC0-∞ = AUC0-t+*Ct/Kel 
Where *Ct is the last detectable plasma concentration.  
The sampling period covered more than 96% of the total AUCs for 
both reference and test. The apparent elimination half-life (t1/2) of 
drug and in plasma was calculated by using the following equation,  
t½ = (ln 2)/Kel 
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The ratio of Cmax/AUC0-∞ was also computed and used as a 
measure for the rate of absorption.  
Statistical analysis 
All values are expressed as the mean±standard deviation (SD). The 
pharmacokinetic parameters obtained by following a single dose 
administration of the marketed product and the optimized 
formulation to normal Rabbits were compared using paired ‘t’ test, 
considering a probability of P<0.05 to be significant.  
Bioavailability and statistical analysis were performed according to 
the Food and Drug Administration (FDA) guidelines by using a 
software Bear v2.5.3  
RESULTS  
Physiochemical properties of suspension 
Physiochemical properties of reconstituted suspension were tested 
as part of quality control tests, the results of which are shown in 
table 3. 
 
Table 3: Physiochemical properties of suspension 
S. No. Tests Formulations 
1:1 1:2 1:2.5 1:3 
1 Color White White White White 
2 pH (Limit: 3.5 to 7) 5.98 6.01 5.92 6.02 
3 Viscosity 319cps 340cps 395cps 410cps 
4 Redispersibility Easy Easy Easy Easy 
5 Pourability Easily Pourable Easily Pourable Easily Pourable Easily Pourable 
6 Assay (Limit: 90 to 110 %) 97.85 % 96.89 % 99.50 % 97.68 % 
Cefuroxime axetil dry suspension was reconstituted with an adequate quantity of water. The color of the suspensions was observed to be white. The pH 
of all the formulations was within the specified limit of 3.5 to 7 as in USP. Adequate viscosity was observed in all the formulations, providing sufficient 
stability and pourability of suspension. All the formulations were easy to redisperse with water by shaking by hand for some time. All the suspensions 
were easily pourable making it easy to dispense. The Assay of all the formulations was meeting the specified limit of 90 to 110 % as per USP. 
 
In-vitro dissolution studies 
In-vitro dissolution of all the combinations and market sample were 
tested using ELECTROLAB dissolution apparatus as per the method 
specified in United States Pharmacopoeia. The results of in-vitro 
dissolution studies are given in fig. 1. 
 
 
Fig. 1: In-vitro dissolution studies-All values are represented as 
mean, n=6 
 
From the dissolution studies, it was found that all the formulations 
and marketed sample were meeting the dissolution criteria of not 
less than 60 % (Q) in 30 min. Among these formulation 1:2.5 seemed 
to have better release pattern than the marketed sample. 
Pharmacokinetic study 
The pharmacokinetic evaluation of optimized formulation and 
marketed product was carried out using a single dose, two-way 
crossover design study on six healthy male rabbits. The Plasma drug 
concentrations at different time intervals for optimized formulation 
and Marketed Product are presented in fig. 2 and the major 
pharmacokinetic parameters are presented in table 4. 
 
 
Fig. 2: Plasma drug concentrations at different time intervals 
for optimized formulation and marketed product 
 
Various pharmacokinetic parameters were calculated during the 
study, from which the Cmax of optimized formulation and marketed 
product were found to be 148±1.26ng/ml and 126±1.52 ng/ml 
respectively, and the AUC0-t 
 
optimized formulation and marketed 
product were 989±16.42 ng. h/ml and 613±24.26 ng. h/ml 
respectively, which shows a significant improvement in the 
bioavailability of optimized formulation, compared to the marketed 
product.
Table 4: Comparison of pharmacokinetic parameters of optimized formulation and Marketed Product 
Parameters Optimized formulation Marketed product 
Cmax 148±1.26 (ng/ml) 126±1.52 
AUC0-t 989±16.42 (ng. h/ml) 613±24.26 
AUC0-∞ 1225±38.54 (ng. h/ml) 1004±35.14 
Tmax 6.00±1.23  (h) 4.50±0.24 
t1/2 3.05±0.519  (h) 1.56±0.01 
Kel (h-1 2.807±0.11 ) 2.189±0.33 
Each value is mean±SEM of 6 rabbits in each group 
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In this study attempt has been made to improve the oral 
bioavailability of Cefuroxime axetil oral suspension 125 mg by 
inclusion complexation method using HP-Beta-cylcodextrin. The 
optimized formulation is better in taste, dissolution and 
bioavailability compared to the marketed product. Many studies are 
available for the improvement of bioavailability of Cefuroxime axetil 
with plain Beta-cyclodextrin [1, 2]. In this study, HP-Beta-
cylcodextrin is selected instead of plain Beta-cyclodextrin due to its 
improved water solubility and safety profile [16]. So it is an 
additional advantage to the patients to have tastier, efficient and 
safer medicine. Some other studies are available for masking the 
bitter taste of Cefuroxime axetil, like spray drying technique with 
Stearic acid, complexation with ion exchange resins, etc, but non of 
them claim to have improved the bioavailability of oral 
suspension[18]. 
CONCLUSION 
An oral suspension of Cefuroxime axetil was successfully developed 
by inclusion complexation method using HP-Beta-cylcodextrin. All 
the formulations developed were subjected to various quality 
control tests including physiochemical parameters and in-vitro 
dissolution, where all the formulations were meeting the quality 
parameters. Among the four formulations prepared formulation 
with 1:2.5 ratios of Cefuroxime axetil and HP-Beta-cylcodextrin 
showed improved dissolution compared to the marketed product. So 
formulation with 1:2.5 ratios was selected as the optimized 
formulation. The optimized formulation and the marketed product 
were subjected to pharmacokinetic study using healthy male rabbits, 
which the results shows a significant improvement in the 
bioavailability of optimized formulation compared to the marketed 
product. This demonstrates that the inclusion complexation method 
with HP-Beta-cylcodextrin can significantly improve the oral 
bioavailability of Cefuroxime axetil. 
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